Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961621 | 1.00 | MCL1 (0.32) | MCL1LMNAMAPTSMN1; SMN2PKM | |
| SCHEMBL965978 | 0.93 | KDM4E (0.32) | MCL1MAPTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL965979 | 0.93 | KDM4E (0.32) | MCL1MAPTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL964970 | 0.91 | MTNR1A (0.39) | MTNR1AMTNR1BHDAC1 | |
| SCHEMBL964972 | 0.91 | MTNR1A (0.39) | MTNR1AMTNR1BHDAC1 | |
| SCHEMBL966394 | 0.90 | PPARG (0.38) | MCL1PPARGMTNR1AMTNR1B | |
| SCHEMBL966393 | 0.90 | PPARG (0.38) | MCL1PPARGMTNR1AMTNR1B | |
| SCHEMBL965208 | 0.89 | PIM3 (0.34) | PPARGMTNR1AMTNR1BHDAC1 | |
| SCHEMBL965210 | 0.89 | PIM3 (0.34) | PPARGMTNR1AMTNR1BHDAC1 | |
| SCHEMBL967666 | 0.89 | MTNR1A (0.31) | MTNR1AMTNR1BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | MCL1 3194/4885LMNA 3775/4885MAPT 4343/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | MCL1 3693/4885LMNA 3461/4885MAPT 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.